Graft-Versus-Host Disease

A short course of itacitinib induced high response rates among patients with low-risk acute graft-versus-host disease, according to study results.

In the latest installment of Residency to Retirement, experts outlined five success factors that physicians should consider incorporating into their permanent life insurance policy.

NEW ORLEANS — Most hematopoietic stem cell transplant recipients received at least one dose of COVID-19 vaccine, according to single-institution study results presented at ASH Annual Meeting and Exposition.

The FDA approved ibrutinib for children with chronic graft-versus-host disease.

SALT LAKE CITY — Ibrutinib appeared safe and effective for children with previously untreated or relapsed/refractory chronic graft-versus-host disease, according to study results.

SALT LAKE CITY — Axatilimab appeared effective for heavily pretreated patients with active chronic graft-versus-host disease, according to phase 1/phase 2 study results.

SALT LAKE CITY — Abatacept demonstrated efficacy among patients with steroid-refractory chronic graft-versus-host-disease, according to phase 2 study results.

BOSTON – Loriel J. Solodokin, PharmD, BCOP, talked about the “innovative research” presented at the poster sessions at Hematology/Oncology Pharmacy Association Annual Meeting in a video interview.

Depletion of naive T cells from peripheral blood stem cell grafts resulted in very low incidence of severe acute and any graft-versus-host disease in three phase 2 clinical trials, according to a study in Journal of Clinical Oncology.

The FDA approved abatacept in combination with a calcineurin inhibitor and methotrexate for prevention of acute graft versus host disease.